What are the risks of using lurbinectedin while breastfeeding?

What happens to lurbinectedin in breast milk?
Lurbinectedin is a small-molecule alkylating agent given by intravenous infusion. No published data show whether the drug or its metabolites pass into human breast milk or what concentrations might reach an infant.

Can a nursing infant be exposed through breast milk?
Because the drug has not been measured in milk, exposure risk cannot be quantified. The same lack of data applies to its elimination half-life in milk or the duration any residues would remain.

How long should breastfeeding be paused after a dose?
Without milk-transfer studies, clinicians typically recommend stopping breastfeeding during treatment and for at least one week after the last infusion, matching the drug’s plasma half-life of roughly 30 hours. Some centers extend this interval to two weeks for added caution.

What side effects might a breastfed infant experience?
If exposure occurred, the infant could face the same toxicities seen in adults: bone-marrow suppression, liver-enzyme elevations, nausea, fatigue, and potential DNA-damaging effects. No case reports document these outcomes in nursing infants.

Are there alternatives for mothers who need lurbinectedin?
Pumping and discarding milk during the treatment window, or switching to formula, are the practical options. No established lactation-compatible substitute exists for the same indication.

When does the drug’s label address lactation?
The prescribing information states that women should not breastfeed during therapy and for one week after the final dose, citing the potential for serious adverse reactions in the breastfed child.